1059705-52-0

Basic information

• Product Name: 1-(3-chloro-4-nitrophenyl)-4-methylpiperazine
• Synonyms: 1-(3-chloro-4-nitrophenyl)-4-methylpiperazine
• CAS NO: 1059705-52-0
• Molecular Weight: 255.704
• Mol File: 1059705-52-0.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 404.2±45.0 °C(Predicted)
• Density: 1.300±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 1-(3-chloro-4-nitrophenyl)-4-methylpiperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-chloro-4-nitrophenyl)-4-methylpiperazine(1059705-52-0)
• EPA Substance Registry System: 1-(3-chloro-4-nitrophenyl)-4-methylpiperazine(1059705-52-0)

Safety Data

• Hazardous Substances Data: 1059705-52-0(Hazardous Substances Data)

Usage

Structure

Piperazine ring with a chloro-nitrophenyl group and a methyl group attached

Usage

Intermediate in the synthesis of pharmaceuticals

Application

Antipsychotic and antidepressant medications

Therapeutic effects

Potential effects on mental health disorders such as schizophrenia and depression

Other studies

Activity as an insecticide and antimicrobial agent

Importance

Potential applications in pharmaceutical and agricultural industries

Upstream product

• 109-01-3 1-methyl-piperazine 
• 89465-97-4 4-bromo-2-chloro-1-nitrobenzene 
• 23491-48-7 5-(4-methylpiperazine-1-yl)-2-nitroaniline 
• 2369-11-1 5-fluoro-2-nitroaniline 
• 2106-50-5 2-chloro-4-fluoro-1-nitrobenzene 
• 14593-46-5 sodium tert-pentoxide 

Downstream Products

• 1124330-00-2 2-chloro-4-(4-methylpiperazine-1-yl)aniline 

Relevant articles and documents

Optimization of WZ4003 as NUAK inhibitors against human colorectal cancer

NUAK, the member of AMPK (AMP-activated protein kinase) family of protein kinases, is phosphorylated and activated by the LKB1 (liver kinase B1) tumor suppressor protein kinase. Recent work has indicated that NUAK1 is a key component of the antioxidant stress response pathway, and the inhibition of NUAK1 will suppress the growth and survival of colorectal tumors. As a promising target for anticancer drugs, few inhibitors of NUAK were developed. With this goal in mind, based on NUAK inhibitor WZ4003, a series of derivatives has been synthesized and evaluated for anticancer activity. Compound 9q, a derivative of WZ4003 by removing a methoxy group, was found to be the most potential one with stronger inhibitory against NUAK1/2 enzyme activity, tumor cell proliferation and inducing apoptosis of tumor cells. By in vivo efficacy evaluations of colorectal SW480 xenografts, 9q suppresses tumor growth more effectively with an excellent safety profile in vivo and is therefore seen as a suitable candidate for further investigation.

Pyrazolopyrimidines and related heterocycles as CK2 inhibitors

The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and have the following general formula:

2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: Modification of target structure to minimize reactive metabolite formation

The JAK2/STAT pathway has important roles in hematopoiesis. With the discovery of the JAK2 V617F mutation and its presence in many patients with myeloproliferative neoplasms, research in the JAK2 inhibitor arena has dramatically increased. We report a nov